SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Hot Topics > Lifecycle management

FDA biosimilar guidance permits alternative drug delivery devices

3 commentsBy Nick Taylor , 13-Feb-2012
Last updated on 13-Feb-2012 at 09:00 GMT

The FDA has said biosimilars can use different drug delivery devices than their reference products in its long-awaited guidance.

Industry has called for US Food and Drug Administration (FDA) guidance on biosimilars since Congress created an abbreviated approval pathway in 2010. The wait is now over. In three documents the FDA has laid out its thinking on biosimilars, including the use of alternative drug delivery devices.

Some design differences in the delivery device or container closure system used with the proposed biosimilar product may be acceptable”, the FDA wrote in one of three biosimilar draft guidance question and answer documents it released.

If a company gives the FDA adequate data it can package its biosimilar in a pre-filled syringe or auto-injector device, even if the reference product was sold in vials. Using an alternative device could allow biosimilar developers to gain an edge over innovators by improving compliance.

The challenge will be convincing the FDA to approve the change. Companies must show that the new device or closure system is compatible with the biosimilar formulation by running studies on stability, leachables and other factors. Biosimilars must have the sameroute of administration as references.

Applications must also consider whether the delivery device will limit ability to switch between a biosimilar and its reference product. The FDA will look at whether the device necessitates added instruction to patients or healthcare providers, as well as changes to other factors, such as design attributes.

If the changes are too significant the FDA will reject applications. Any device that creates a ‘clinically meaningful difference’ between the safety, purity, and potency of a biosimilar and its reference will be rejected.

Additional work may be needed to support some applications. “A proposed biosimilar product in a delivery device will be considered a combination product and may, in some instances, require a separate application for the device”, the FDA wrote.

Biosimilar excipients

Differences between the formulation of a biosimilar and its reference may also be acceptable. Again, it comes down to data. Applicants must show that the biosimilar is ‘highly similar’ even if there are minor differences in its use of excipients.

It may be possible, for example, for a proposed product formulated without human serum albumin to demonstrate biosimilarity to a reference product formulated with human serum albumin”, the FDA wrote.

Requirements for active ingredients are tighter. In general, biosimilars must have the same amount and concentration of drug substance as reference products, but for some complex biologics ‘a modified approach may be needed’.

3 comments (Comments are now closed)

thanks for your insights

thanks so much for your rapid response. will review it in the morning. need to catch some zzzzz now.

Report abuse

Posted by robin hwang
21 February 2012 | 09h52

@Robin Hwang

Hi Robert,

Thanks for your interest and sorry if it wasn't clear from the article.

In the document the FDA poses the following question:

'Can a proposed biosimilar product have a delivery device or container closure system that is different from its reference product?'

Its answer is:

'Yes, some design differences in the delivery device or container closure system used with the proposed biosimilar product may be acceptable.

'It may be possible, for example, for an applicant to obtain licensure of a proposed biosimilar product in a pre-filled syringe or in an auto-injector device, even if the reference product is licensed in a vial presentation.'

Here's the doc: http://1.usa.gov/A2tS0s

Hope that helps.

Nick

Report abuse

Posted by Nick Taylor
21 February 2012 | 09h10

FDA biosimilar guidance permits alternative drug delivery devices?

I quickly reviewed the three draft guidances but did not really see the implication of how "FDA biosimilar guidance permits alternative drug delivery devices". What made you reach that comment? I would appreciate your insights. Thanks.

Report abuse

Posted by robin hwang
21 February 2012 | 08h57

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry